Parkinson s disease. Information for patients and carers. The Leeds Teaching Hospitals NHS Trust

Similar documents
Appendix 2: Admissions checklists for people with Parkinson s

An Overview of Parkinson s Medication used in Multiple System Atrophy

An Overview of Parkinson s Medication used in Multiple System Atrophy

PARKINSON S MEDICATION

Guidelines for acute treatment of patients with Parkinson s disease including those who are nil by mouth

Acute management of in-patient Parkinson s Disease patients

ACUTE MANAGEMENT OF PARKINSON S PATIENTS WHO ARE NIL BY MOUTH (NBM) OR WHO HAVE A COMPROMISED SWALLOW NHS LANARKSHIRE PARKINSON S TEAM

Parkinson s Well-Being Map TM

Medications used to treat Parkinson s disease

Best Medical Treatments for Parkinson s disease

The symptoms of the Parkinson s disease may vary from person to person. The symptoms might include the following:

Motor Fluctuations Stephen Grill, MD, PHD Parkinson s and Movement Disorders Center of Maryland and Johns Hopkins University

MANAGEMENT OF PATIENTS WITH PARKINSON S DISEASE WHO ARE NIL BY MOUTH OR WITH A COMPROMISED SWALLOW

Commonly encountered medications and their side effects - what the generalist needs to know

Summary of Patient < 3y at Visit 11 (90 months)

parts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to

Clinical Guideline for the management of inpatients with Parkinson s disease

Pharmacy Coverage Guidelines are subject to change as new information becomes available.

Communicating About OFF Episodes With Your Doctor

Optimizing Clinical Communication in Parkinson s Disease:

Management of Parkinson s Disease in Primary and Secondary care for patients with compromised swallow or those patients deemed Nil By Mouth.

Let s Look at Parkinson s (PD) Sheena Morgan Parkinson s Disease Nurse Specialist Isle of Wight NHS Trust November 2016

Parkinson s Disease Medications: Professionals Edition

Thinking about advanced parkinson S

Parkinson's Disease and how you can make a difference with medication

Recent Advances in the cause and treatment of Parkinson disease. Anthony Schapira Head of Dept. Clinical Neurosciences UCL Institute of Neurology UCL

Medication Management & Strategies When the levodopa honeymoon is over

Dorset Medicines Advisory Group SHARED CARE GUIDELINES FOR PRESCRIBING ENTACAPONE (INCLUDING IN COMBINATION) OR OPICAPONE IN PARKINSON S DISEASE

Scottish Medicines Consortium

10th Medicine Review Course st July Prakash Kumar

What s new for diagnosing and treating Parkinson s Disease?

Parkinson s Disease Prescribing Guidelines for use in Primary and Secondary Care

Objectives. Emerging Treatments in Parkinson s s Disease. Pathology. As Parkinson s progresses it eventually affects large portions of the brain.

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Assistant Professor of Neurology

Parkinson s Disease. Gillian Sare

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Associate Professor of Neurology

History Parkinson`s disease. Parkinson's disease was first formally described in 1817 by a London physician named James Parkinson

Key Concepts and Issues in Parkinson s Disease in 2016

A Review on Parkinson s Disease: Its Surgical Inventional Therapies, Pathophysiology and Treatment

Drugs for Parkinson s Disease

Literature Scan: Anti-Parkinson s Agents

A Review on Parkinson s Disease: Its Pathophysiology, Treatment and Surgery

Treatment of Parkinson s Disease and of Spasticity. Satpal Singh Pharmacology and Toxicology 3223 JSMBS

Advanced Therapies for Motor Symptoms in PD. Matthew Boyce MD

Parkinson s Disease Current Treatment Options

Treatment of Parkinson s Disease: Present and Future

Parkinson s disease: diagnosis and current management

Anticholinergics. COMT* Inhibitors. Dopaminergic Agents. Dopamine Agonists. Combination Product

PD: Key Treatment Considerations

TRANSPARENCY COMMITTEE OPINION. 18 March 2009

PD ExpertBriefings: Parkinson s Medications: Today and Tomorrow Led By: Cynthia L. Comella, M.D., F.A.A.N.

05-Nov-15. Impact of Parkinson s Disease in Australia. The Nature of Parkinson s disease 21st Century

What is Parkinson s Disease?

CLINICAL GUIDELINE FOR THE MANAGEMENT OF INPATIENTS WITH PARKINSON S DISEASE

Re-Submission. Scottish Medicines Consortium. rasagiline 1mg tablet (Azilect ) (No. 255/06) Lundbeck Ltd / Teva Pharmaceuticals Ltd.

Final Appraisal Report. ) for the treatment of idiopathic Parkinson s disease. Ropinirole prolonged-release (Requip XL. GlaxoSmithKline UK

Parkinson s disease Therapeutic strategies. Surat Tanprawate, MD Division of Neurology University of Chiang Mai

The Shaking Palsy of 1817

2-The age at onset of PD is variable, usually between 50 and 80 years, with a mean onset of 55 years (1).

Scott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE

REFERENCE CODE GDHC235CFR PUBLICAT ION DATE M ARCH 2014 PARKINSON S DISEASE - US DRUG FORECAST AND MARKET ANALYSIS TO 2022

CENTENE PHARMACY AND THERAPEUTICS NEW DRUG REVIEW 3Q17 July August

Cardinal Features of Parkinson s. Management of Parkinson s Disease. Drug Induced Parkinson s. Other Parkinson s Symptoms.

Pharmacy Coverage Guidelines are subject to change as new information becomes available.

Clinical Policy: Safinamide (Xadago) Reference Number: CP.CPA.308 Effective Date: Last Review Date: Line of Business: Commercial

Drug Therapy of Parkinsonism. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

New Medicines Committee Briefing July 2011

REFERENCE CODE GDHC237CFR PUBLICAT ION DATE M ARCH 2014 PARKINSON S DISEASE - JAPAN DRUG FORECAST AND MARKET ANALYSIS TO 2022

Novel approaches to the pharmacological treatment of Parkinson s disease. Peter Jenner King s College UK

What is the best medical therapy for early Parkinson's disease? Medications Commonly Used for Parkinson's Disease

Welcome and Introductions

Evaluation and Management of Parkinson s Disease in the Older Patient

Parkinson s Disease Update. Colleen Peach, RN, MSN, FNP Movement Disorders Clinic Emory University School of Medicine March 7, 2015

Early Treatment Options When to start, what with, and why?

Understanding Parkinson s Disease Important information for you and your loved ones

GUIDELINES FOR THE MANAGEMENT OF PATIENTS WITH PARKINSON S DISEASE (PD) ADMITTED TO HOSPITAL. Reviewer s Name, Title & address:

Guideline for the Management of Parkinson s Disease Medication Trust Reference B26/2017

Parkinson s Pharmacology

Program Highlights. Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone Medical Center New York, New York

Parkinson's Disease KP Update

Continuous dopaminergic stimulation

Parkinson s Disease. Medications

XADAGO (safinamide) oral tablet

Parkinsons Disease update. Sindhu R Srivatsal MD MPH Virginia Mason Medical Center

475 GERIATRIC PSYCHOPHARMACOLOGY (p.1)

Welcome and Introductions

Advances in Parkinson s Disease Treatment. Ryan J. Uitti, M.D. Professor of Neurology Mayo Clinic, Jacksonville, FL

WHAT DEFINES YOPD? HANDLING UNIQUE CONCERNS REBECCA GILBERT, MD, PHD VICE PRESIDENT, CHIEF SCIENTIFIC OFFICER, APDA MARCH 14, 2019

Parkinson s Disease Update. Presented by Joanna O Leary, MD Movement disorder neurologist Providence St. Vincent s

Sleep and Night-time Problems in Parkinson s

Parkinsonism. Parkinsonism. James Parkinson A syndrome. Causes of Parkinsonism

Common medicines given to neurology patients on discharge from hospital

The Role of Pharmacists in Treating & Managing Parkinson s Disease Author: Mary Jo Carden, RPh, JD Principal, Carden Associates

Parkinson s Disease WHERE HAVE WE BEEN, WHERE ARE WE HEADING? CHARLECE HUGHES D.O.

THE ART OF MEDICATION MANAGEMENT IN PARKINSON S DISEASE

9/26/18. Objectives. Disclosures. Parkinson s Disease Update Clinical and Operational Considerations

PARKINSON S DISEASE. Nigrostriatal Dopaminergic Neurons 5/11/16 CARDINAL FEATURES OF PARKINSON S DISEASE. Parkinson s disease

REVIEW

Dependency and transfer incomes in idiopathic Parkinson s disease

Transcription:

n The Leeds Teaching Hospitals NHS Trust Parkinson s disease Information for patients and carers in partnership with Leeds Community Healthcare NHS Trust

The symptoms of Parkinson s appear when the levels of a chemical messenger in your brain called dopamine become too low. The cells in your brain that produce dopamine have died or are dying. Currently there is no cure but there is lots of promising research into the causes of Parkinson s, new treatments and finding a cure. What is Parkinson s? The diagnosis of Parkinson s is based on the presence of a number of core symptoms and a physical examination. The four common features are tremor, slowness of movement, muscle stiffness and loss of balance. There may be other symptoms affecting movement, such as hesitation when beginning to walk, small hand writing or reduced facial expression. Non-motor symptoms can also occur such as constipation and vivid dreams. These symptoms have often been present long before the change in movement becomes apparent. Each person with Parkinson s will experience a different range of symptoms and these will change over time. For some people the condition progresses quickly and in others it does not. Regular contact with a Parkinson s specialist is recommended to ensure that your medication is tailored to relieve your individual symptoms. There are many treatments available and it is common for people to take more than one medication. Often multiple doses are needed each day. 2

The regimens can be complex and the Parkinson s nurse specialists are able to offer advice and support in managing your individual requirements. A brief guide to treatment options available for Parkinson s Levodopa is converted into dopamine in the brain. Levodopa is combined with benserazide or carbidopa, this helps the levodopa get into the brain where it s needed. Co-beneldopa (levodopa and benserazide) available as unbranded and Madopar standard release capsules and dispersible tablets and controlled release (CR) capsules. Co-careldopa (carbidopa and levodopa) available as unbranded and brand names Caramet CR tablets, Sinemet, Sinemet Plus, Sinemet CR, Half Sinemet CR tablets and Lecado CR tablets. Duodopa (levodopa and carbidopa) intestinal gel delivered through a tube into the small intestine. This is an advanced treatment used in later stage Parkinson s. Co-careldopa and entacapone available as Stalevo, Sastravi and Stanek tablet, (See also COMT inhibitors). Dopamine Agonists Dopamine Agonists act like dopamine to stimulate your nerve cells. Pramipexole as unbranded tablets and Mirapexin (brand name) standard release and prolonged release tablets. 3

Ropinirole available as unbranded tablets, Adartrel, Aimpart XL, Eppinix XL Ralnea XL, Raponer XL, Repinex XL Requip, Requip XL, Ropilynz XL, Spiroco XL prolonged release tablets. Rotigotine and Neupro (brand name) patches. Apomorphine injections Available as Apo-go intermittent injection pens and Apo-go pre-filled syringes used continuously with an infusion pump. The following dopamine agonists are available but are not widely used due to the increased risk of heart problems. Bromocriptine unbranded and Parlodel tablets and capsules. Cabergoline and Cabaser tablets. Pergolide tablets. Monoamine oxidase-b inhibitors (MAO-B inhibitors) MAOB-inhibitors can help the nerve cells make better use of the dopamine that it does have. They block an enzyme called monoamine oxidase type B which breaks down dopamine in your brain. This helps increase the amount of dopamine in your brain which can help relieve the symptoms of Parkinson s. They can be taken alone or alongside other Parkinson s medication. Rasagiline available unbranded and Azilect (brand name) once a day tablets. Selegiline available unbranded and as Eldepryl and Zelapar (brand names) once a day tablets. 4

Safinamide (brand name Xadago). COMT inhibitors COMT inhibitors work by blocking the enzyme that breaks down levodopa. They are taken with your levodopa. It can be used when your levodopa is not lasting long enough (end-ofdose deterioration) or the effects wear off. Entacapone available unbranded or as Comtess (brand name). Co-careldopa and entacapone in one tablet are available as Stalevo, Sastravi and Stanek. Opicapone (brand name Ongentys) Tolcapone available unbranded and as Tasmar. Glutamate Antagonists It is not known exactly how this drug works but may affect how the brain reacts to certain chemicals. Available as Amantadine and Symmetrel in capsules and syrup. Amantadine is not used very often in early Parkinson s but can be used to help with dyskinesia (involuntary movements). Anticholinergics These drugs block the action of a chemical messenger acetylcholine, this chemical helps send messages in the brain and around your body and nerves in your muscles. These drugs can be used in younger patients and for treating tremor. 5

Available in liquid, syrup and tablets unbranded as orphenadrine and as Biorphen. Procyclidine unbranded and as Arpicolin, kemadrin. Trihexyphenidyl also known as Benzhexol. Deep Brain Stimulation Deep Brain Stimulation (DBS) surgery is an option used in later stage Parkinson s to treat tremor and dyskinesia. This is not a cure and you will still need to take medication. The Role of the Parkinson s Nurse Specialist Team A source of help, support and information for you, your carers and health professionals. To provide advice over the telephone or by email and to review you either in the clinic or at home. The Nurse Specialist team will: Work with your Consultant, GP and other health professionals to optimise your treatment plan. Provide information about medication, help when starting new treatments and advice on long term monitoring. Refer you to other health care professionals such as physiotherapists, the speech and swallowing team, community occupational therapists and the community matrons where appropriate. 6

You may be referred to the team by your Consultant, your GP or another health or social care professional. Self-referrals or referrals from a family member are also welcome. Contact details for the Parkinson s nurse specialist team: Leeds Teaching Hospitals: 0113 392 6689 Leeds Community Health: 0113 855 5082 Team email: pd.nurse@nhs.net Useful contact numbers and sources of information Parkinson s UK - www.parkinsons.org.uk Free national confidential helpline - Tel: 0808 800 0303 Email: hello@parkinsons.org.uk Parkinson s UK local advisors provide: One to one information and support, liaising with health professionals, links to social services and information about benefits and how to claim them. Tel: Cate Scally: 0344 225 3766 Email: cscally@parkinsons.org.uk Yorkshire and Humberside Younger Persons Support Group - www.parkinsonsypsg.org The Cure Parkinson s Trust - www.cureparkinsons.org.uk Tel: 020 7487 3892 Email: cptinfo@cureparkinsons.org.uk Carers UK - www.carersuk.org Advice Line: 0808 808 7777 Driving and Parkinson s disease When you are diagnosed with Parkinson s you are legally obliged to inform the Driver and Vehicle Licensing Agency (DVLA). Tel: 0300 790 6802 Website: www.dvla.gov.uk 7

The Leeds Teaching Hospitals NHS Trust 3rd edition (Ver 1) Developed by: Philippa Duggan-Carter, Parkinson s Clinical Nurse Specialist and Dr Dagmar Long, Associate Specialist in Neurology and Consultant Community Geriatrician. Produced by: Medical Illustration Services MID code: 20161213007/JG LN003320 Publication date 05/2017 Review date 05/2019